<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565500</url>
  </required_header>
  <id_info>
    <org_study_id>635-IFL-0508-017</org_study_id>
    <secondary_id>N49-98-71-900</secondary_id>
    <nct_id>NCT00565500</nct_id>
  </id_info>
  <brief_title>Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin</brief_title>
  <official_title>A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chieti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design: Single center, placebo-controlled, double blind, parallel groups. To evaluate
      the potential interaction between aspirin and ibuprofen or celecoxib in patients with
      osteoarthritis (OA) and documented stable ischemic heart disease, a total of 24 patients
      chronically treated with aspirin will be randomly assigned to one of the 3 treatment groups:
      1) celecoxib 200 mg bid; 2) ibuprofen 600 mg tid; 3) placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with arthritis and vascular disease may receive both NSAIDs and lowdose aspirin for
      the secondary prevention of important vascular events. The use of COX-2 inhibitors may have
      the potential advantage vs. nonselective NSAIDs in reducing the probability of interfering
      with permanent inactivation of COX-1 platelet by low-dose aspirin, in this setting. In fact,
      recent studies suggest that the likelihood of COX-inhibitors to present this pharmacodynamic
      interaction is inversely related to their COX-2 selectivity. Thus, differently from the
      non-selective NSAID ibuprofen, prior administration of the selective COX-2 inhibitor
      rofecoxib, does not antagonize the irreversible inhibition induced by aspirin in healthy
      subjects. Aim of this study is to determine whether celecoxib given at therapeutic dose at
      steady state alters the antiplatelet activity of low-dose aspirin, in comparison with
      ibuprofen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum thromboxane (TX)B2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>urinary 11-dehydro-thromboxane (TX)B2, arachidonic acid- and ADP-induced platelet aggregation by Born's aggregometer, whole-blood aggregation in the platelet function analyzer (PFA) system, LPS-stimulated prostaglandin(PG)E2</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>celecoxib capsules 200 mg bid for 1 week</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen</intervention_name>
    <description>ibuprofen tablets 600 mg tid for 1 week</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsules tid for 1 week</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male or female, age 18-75;

          2. subjects with osteoarthritis and documented stable ischemic heart disease;

          3. the patient is on long-term aspirin prophylaxis for the ischemic condition;

          4. the patient requires or is eligible for chronic treatment with an antiinflammatory
             and/or analgesic drugs given to control osteoarthritis symptoms;

          5. female subjects of childbearing potential must have a negative pregnancy test, use
             adequate contraception during the study and not be lactating;

          6. written informed consent before undergoing any study procedure.

        Exclusion Criteria:

          1. active gastrointestinal disease (e.g. Crohn's disease or ulcerative colitis) or any
             evidence of concomitant disease which may lead to early termination of the study;

          2. history of active peptic ulceration, gastrointestinal bleeding, esophageal, gastric or
             duodenal ulcer;

          3. known hypersensitivity to COX-2 inhibitors, analgesics, antipyretics, sulfonamides or
             NSAIDs;

          4. treatment with any investigational drug within the previous 30 days;

          5. previous participation in this study;

          6. evidence of neoplasm or any other severe disease of any organ, including any
             psychiatric illness;

          7. clinically relevant deviations from the normal range in laboratory tests;

          8. recent history or suspicion of alcohol abuse or drug addiction;

          9. subjects unlikely to be collaborative or to give reliable answers;

         10. pregnancy or lactation; female or childbearing potential without a clinical accepted
             contraceptive method;

         11. any severe pathology that can interfere with the treatment or the clinical or
             instrumental tests of the trial;

         12. intake of antiaggregant, anticoagulant, diuretic, beta-blocker, ACE- inhibitor,
             lithium, methotrexate, cimetidine, digoxin;

         13. contraindications to NSAIDs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raffaele De Caterina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cardiology, G. d'Annunzio University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ce.S.I., Center of Excellence on Aging, G. d'Annunzio University</name>
      <address>
        <city>Chieti</city>
        <state>CH</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest. 2001 Jan;119(1 Suppl):39S-63S. Review.</citation>
    <PMID>11157642</PMID>
  </reference>
  <reference>
    <citation>Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366-72.</citation>
    <PMID>7045161</PMID>
  </reference>
  <reference>
    <citation>Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809-17.</citation>
    <PMID>11752357</PMID>
  </reference>
  <reference>
    <citation>FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001 Aug 9;345(6):433-42. Review.</citation>
    <PMID>11496855</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <last_update_submitted>November 29, 2007</last_update_submitted>
  <last_update_submitted_qc>November 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2007</last_update_posted>
  <responsible_party>
    <name_title>Raffaele De Caterina, MD, PhD</name_title>
    <organization>G. d'Annunzio University - Chieti</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

